HSIC — Henry Schein, Inc.

Summary of Henry Schein's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Sales: $3.3 billion, a growth of 5.2% year-over-year, with constant currency growth of 4.0%.
• GAAP Net Income: $101 million ($0.84 per diluted share), compared to $99 million ($0.78 per diluted share) in Q3 2024.
• Non-GAAP Net Income: $167 million ($1.38 per diluted share), up from $155 million ($1.22 per diluted share) in the prior year.
• Adjusted EBITDA: $295 million, a 10% increase from $268 million in Q3 2024.
• Operating Margin: GAAP operating margin at 4.88% (down 6 basis points), while non-GAAP operating margin improved to 7.83% (up 19 basis points).
• Effective Tax Rate: Non-GAAP effective tax rate was 22.9%, expected to rise to 24-25% in Q4.

2. Strategic Updates and Business Highlights

• BOLD+1 Strategy: Continued execution with a focus on high-growth, high-margin businesses, targeting over 50% of non-GAAP operating income from these segments by 2027.
• Value Creation Initiatives: Aiming for $200 million in operating income improvements over the next few years, with a focus on centralizing support services and enhancing corporate brand sales.
• Share Repurchase Program: Increased by $750 million; $229 million spent in Q3 to repurchase 3.3 million shares.
• E-commerce Expansion: Launched a new global eCommerce platform in the U.K. and Ireland, with plans for a phased rollout in North America and Europe in 2026.
• Strong Performance in Specialty Products: Notable growth in implants and biomaterials, with mid-single-digit growth in constant currency.

3. Forward Guidance and Outlook

• 2025 Non-GAAP EPS Guidance: Raised to $4.88 - $4.96, reflecting stable markets and strong Q3 performance.
• Sales Growth Expectation: Now projected at 3% to 4% over 2024.
• Adjusted EBITDA Guidance: Expected to grow in the mid-single digits compared to 2024.
• 2026 Outlook: While specific guidance is not provided, there are expectations for operating improvements driven by ongoing initiatives.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressure: Overall gross margin decreased by 56 basis points, primarily due to product mix issues in the Global Distribution Group and Specialty Products segment.
• Influenza Vaccine Sales Decline: Lower demand for respiratory diagnostic products and influenza vaccines impacted medical sales.
• Cyber Incident Recovery: Although the cyber incident is behind them, it impacted customer relationships and sales momentum previously, requiring ongoing efforts to regain market share.
• Market Stability: While the company is gaining market share, overall market conditions remain stable with slight inflation pressures from tariffs.

5. Notable Q&A Insights

• Market Share Gains: Management expressed confidence in regaining market share post-cyber incident, with a strong sales team and promotional activities contributing to growth.
• KKR Partnership: KKR's increased stake to 19.9% reflects their confidence in the company, with ongoing collaboration on value creation initiatives.
• Specialty Products Margins: The growth in value implants, while beneficial for sales, dilutes margins compared to premium implants, which are essential for profitability.
• Future of the Specialty Business: Management indicated that growth in premium implants and improved operational efficiencies will be critical for EBIT growth in 2026.

Overall, Henry Schein's Q3 2025 results show a positive trajectory in sales and profitability, driven by strategic initiatives and recovery from past challenges, while also highlighting areas for improvement and ongoing market dynamics.